Idarubicin

Speth P. , Minderman H. , Haanen C. : ldarubicin vs. daunorubicin. Preclinical and clinical pharmacokinetic studies . Semin Oncol 16:2-9, 1989 (suppl 2)

Adria Laboratories : Idarubicin product data . Columbus, OH, Adria Laboratories , 1985 (clinical brochure)

Lopez M. , Di Lauro L , et al: Phase II trial with oral idarubicin in advanced breast cancer . Invest New Drugs 4:39-42, 1986

Lopez M. , Contegiacomo A. , Vici P. , et al: A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 64:2431-2436, 1989

Di Marco A , Casazza A. , Prates G. : Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 61:893-894, 1977

Harousseau J. , Reiffers J. , et al: Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 7:45-49, 1989

Carella A. , Santini G. , et al: 4-demethoxydauriorubicin (idarubicin) in refractory or relapsed acute leukemias. Cancer 55:1452-1454, 1985

Wiemik P. , Case D. , et al: A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol 16:25-29, 1989 (suppl 2)

Daghestani A. , Arlin Z. , et al: Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 45:1408-1412, 1985

Eastern Cooperative Oncology Group drug data sheet. ECOG, Atlanta, GA, June 1989 (meeting)